Given its role in cancer progression, TNF has been targeted in various experimental therapies. TNF inhibitors like infliximab and etanercept have been used in clinical trials to assess their efficacy in treating certain types of cancer. The challenge lies in selectively inhibiting TNF's tumor-promoting effects while preserving its tumor-suppressing capabilities. Additionally, anti-TNF therapy is complicated by its potential to impair immune function, which is critical in fighting cancer.
